Pinned Tweet
I spent the last ~2 weeks actively looking for other investment opportunities after $ATAI (which was over 70% of my total holdings) got sold to $LLY.
I have a hard time finding something more interesting than the opportunity that $ABCL presents right now.
They have it all:
- great management
- high insider ownership (with insider buying over the past months)
- exciting and continually diversified platform that’ll potentially be able to produce many best-in-class and first-in-class treatments over the next years
- upcoming Phase 2 readout (ABCL635) for which I am optimistic
-many partnerships, for example with AbbVie, Lilly and as of recently Jazz.
- outstanding liquidity, financing at least the next 3 years. (I would expect milestone payments over the next couple of years would further increase the cash position and therefore make raising capital i.e. diluting shareholders unnecessary.)
I probably forgot even more arguments for an investment but the ones mentioned above are reason enough for an outsized position in my portfolio.
NFA
$ABCL
CFO Andrew Booth just bought 8,600 shares at an average of $11.33, around $97k!
$ABCL
Carl Hansen just bought 60,565 shares at an avg. of $11.54, around $700k!
Rational Money retweeted
Apparently, we aren’t bullish enough on $ABCL.
UBS $18 price target.
$13B commercial opportunity in 2035
$3.3B in risk adjusted 2035 sales
They think there’s a larger market than what other investors anticipate.
Needless to say, I’m long and strong!
🧬 $ABCL
UBS 신규 매수 의견, 목표주가 $18.🎯
핵심은 2035년 매출 전망 $33억.✔️
UBS가 AbCellera에 Buy 의견과 목표주가 $18로 신규 커버리지를 시작했습니다.
제가 주목하는 것은 목표주가 자체보다 ABCL635의 장기
상업적 가치를 시장 예상보다 훨씬 높게 평가했다는 점입니다.
📌 UBS가 제시한 핵심 숫자
• 투자의견: Buy
• 목표주가: $18
• 2035년 폐경 치료 시장 기회: $130억
• UBS의 2035년 위험조정 매출 전망: $33억
• 기사에 인용된 시장 컨센서스: $15억
UBS의 매출 전망은 시장 컨센서스의 약 2.2배입니다.
🔍 왜 이렇게 높게 평가했을까?
첫째, 폐경기 안면홍조 치료 시장의 성장 가능성입니다.
둘째, ABCL635가 효능과 안전성, 투여 편의성을 바탕으로
기존 치료제와 차별화될 가능성입니다.
셋째, UBS는 ABCL635가 현재 투자자들의 예상보다 더 큰 시장점유율을 확보할 수 있다고 판단합니다.
UBS는 ABCL635를 폐경기 안면홍조 치료 분야에서 치료
방식을 바꿀 잠재력이 있는 약물로 평가했습니다.
그렇다면 왜 목표주가는 $18일까요?
장기 매출 전망이 높더라도 Phase 3, 허가, 상업화까지는
여전히 불확실성과 시간이 남아 있기 때문입니다.
특히 UBS의 $33억은 위험조정 매출 추정치이지, 확정 매출이나 현재 기업가치가 아닙니다. 상세 가치평가 가정은 전체 보고서 확인이 필요합니다.
💬 마지막 코멘트
저는 이번 보고서가 ABCL635의 평가 기준이 달라지고 있다는 점에서 의미 있다고 봅니다.
이제 질문은 단순히 임상에서 효과가 있는가를 넘어,
실제 시장에서 얼마나 큰 의약품이 될 수 있는가로 이동하고 있습니다.
다음 관문은 12주 데이터의 효과 지속성, 안전성, 투여 간격과 후기 임상 설계입니다.
ABCL635의 상업적 가치가 입증된다면 첫 번째 의약품의
가치가 높아질 것입니다.
이후 ABCL688·386 등에서 성공이 반복된다면
AbCellera라는 기업 자체를 평가하는 기준도 달라질 수 있습니다.
🔗 참고자료 / PRIMARY SOURCES
TheFly — AbCellera initiated with a Buy at UBS
tipranks.onelink.me/WJho/vw2…
AbCellera — ABCL635 Pipeline
abcellera.com/pipeline/abcl6…
※ 본 글은 공개자료를 바탕으로 확인된 사실과 분석·전망을 구분해 작성했습니다. 특정 종목의 매수·매도 권유가 아닙니다.
Rational Money retweeted
JPM issues a $17 price target on $ABCL:
This line stuck out to me:
“Multitude of Partnerships in Place Validate the Breadth and Standing of the Underlying Technology Platform: The breadth of partnerships at ABCL, in our view, speaks volumes to the differentiation its technology platform holds. We view the partnerships via 40+ partners to-date positively, as they provide continued streams of non-dilutive capital and further refine the platform as a real-world testing ground”.
Great to see the street taking this aspect of AbCellera’s business into consideration
The value of AbCellera lies far beyond ABCL635 alone
$ABCL AbCellera JP Morgan Initiation at $17/share:
"We believe ABCL635’s profile is highly differentiating in multiple folds from the point of efficacy, safety and dosing convenience. ABCL635 delivered the strongest
VMS frequency reduction against other NK-targeted agents, while demonstrating a clean safety profile without the needs of cumbersome bloodwork monitoring and concerns of depression and somnolence. We believe there is a clear disconnect in the perception of the true market potential for a novel product with such profile, based on
our doctor survey we conducted earlier this month."
Rational Money retweeted
$ABCL Over a two-week period, AbCellera insiders have purchased 147,200 shares on the open market, about $1.5M in combined insider buying:
• Director Michael R. Hayden - 53,613 shares at $10.64 ($570.4K) on Aug 24
• Director John S. Montalbano - 10,000 shares at $11.03 ($110.3K) on Aug 18
• CFO Andrew Booth - 37,200 shares at $10.32 ($383.9K) on Aug 14
• Director Michael R. Hayden - 46,387 shares at $10.37 ($481K) on Aug 12
Long and strong 💪
$ABCL
Yes please!! ANOTHER INSIDE PURCHASE.
53,613 shares purchased today at $10.64 today. The writing is on the wall folks. Insiders think that we are going UP.
Long and strong!
d18rn0p25nwr6d.cloudfront.ne…
Rational Money retweeted
$ABCL Insider buying reported today:
CFO Andrew Booth buys 37,200 shares at $10.32
I also don’t understand the people arguing that $ABCL raised too soon.
It’s standard procedure to raise into strength and not wait weeks to raise at possibly higher prices.
There is always the chance that the chart corrects in the short term due to profit-taking, and raising into the weakness that would’ve created would be way worse for shareholders.
I like this news.
Means that $ABCL is better positioned to commercialize ABCL635 themselves.
If they still sought to partner it out, they would be negotiating from a position of strength and therefore getting the best possible deal.
The market might still react negatively in the short-term, but it’s great for the long-term prospects of the company.
4
29
4,260
I like this news.
Means that $ABCL is better positioned to commercialize ABCL635 themselves.
If they still sought to partner it out, they would be negotiating from a position of strength and therefore getting the best possible deal.
The market might still react negatively in the short-term, but it’s great for the long-term prospects of the company.
AbCellera Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants investors.abcellera.com/news…
Rational Money retweeted
AbCellera Announces Positive Top-Line Phase 2 Clinical Trial Results for ABCL635, Demonstrating Significant Reduction in Frequency and Severity of Vasomotor Symptoms and a Favorable Tolerability Profile investors.abcellera.com/news…
Rational Money retweeted
AbCellera to Announce Top-Line Results from the Phase 2 Trial of ABCL635 for the Treatment of Moderate-to-Severe VMS Due to Menopause on Monday, August 10, 2026 investors.abcellera.com/news…
Rational Money retweeted
My long term $ABCL price target isn’t a definitive number. Its this:
AbCellera CEO Carl Hansen on “redefining” what success looks like in Canada:
“One of the things Canada can boast of is terrific science” … “but we are still the only G7 country without a major biopharma company”.
“It’s not because we haven’t had successes. It’s because every time that a success starts to look like it’s going to work, we sell it.” … “If you keep selling your dollar bills for pennies, you’re going to wake up 20 years later and say ‘hey we’ve got no money left’. And we’ve been doing that again and again”.
“In biotech and in other sectors of tech, the reality is you either start a company that is ambitious enough and big enough to scale and be a global champion, or it’s going to get bought. And when it gets bought, it gets bought by companies that are much bigger. And if you don’t have bigger companies, you lose the companies.”
“If there’s one thing that everyone could just get their mind around: We need to build big companies. By whatever means. If we have big companies, we are an acquirer of technology. If we don’t, we are a cheap branch-plant for large multinationals in other jurisdictions.”























